PSMA Theranostics: Current Landscape and Future Outlook.

ABSTRACT:

Introduction

Prostate-specific membrane antigen (PSMA) is a promising novel molecular target for imaging diagnostics and therapeutics (theranostics). There has been a growing body of evidence supporting PSMA theranostics approaches in optimizing the management of prostate cancer and potentially altering its natural history.

Methods

We utilized PubMed and Google Scholar for published studies, and clinicaltrials.gov for planned, ongoing, and completed clinical trials in PSMA theranostics as of June 2021. We presented evolving evidence for various PSMA-targeted radiopharmaceutical agents in the treatment paradigm for prostate cancer, as well as combination treatment strategies with other targeted therapy and immunotherapy. We highlighted the emerging evidence of PSMA and fluoro

SUBMITTER: Zhang H 

PROVIDER: S-EPMC8391520 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature